Bayer Buys Noria Therapeutics and PSMA Therapeutics
03 Junho 2021 - 9:30AM
Dow Jones News
By Pietro Lombardi
Bayer AG has reached an agreement to buy research and
development company Noria Therapeutics Inc. and its subsidiary PSMA
Therapeutics Inc. in a move that broadens its prostate cancer
portfolio.
The target companies, based in New York, have exclusive global
rights to technology licensed from Weill Cornell Medicine and Johns
Hopkins University, the German pharmaceutical and chemical
conglomerate said Thursday.
Financial details of the deal weren't disclosed.
Write to Pietro Lombardi at pietro.lombardi@wsj.com;
@pietrolombard10
(END) Dow Jones Newswires
June 03, 2021 08:28 ET (12:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Bayer (TG:BAYN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024